TCI Wealth Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

TCI Wealth Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16	Closed	-$7.67K	–	451
2023 Q1	$7.67K	Hold	16	–	–	﹤0.01%	1244
2022 Q4	$6.73K	Hold	16	–	–	﹤0.01%	1343
2022 Q3	$7K	Buy	16 +1	+7%	+$499	﹤0.01%	1224
2022 Q2	$7K	Hold	15	–	–	﹤0.01%	1213
2022 Q1	$8K	Sell	15 -3	-17%	-$1.81K	﹤0.01%	1226
2021 Q4	$14K	Buy	18 +3	+20%	+$2.25K	﹤0.01%	903
2021 Q3	$11K	Buy	15 +3	+25%	+$2.25K	﹤0.01%	1016
2021 Q2	$8K	Buy	12 +2	+20%	+$1.22K	﹤0.01%	1090
2021 Q1	$6K	Buy	10 +8	+400%	+$4.74K	﹤0.01%	1121
2020 Q4	$1K	Buy	+2	New	+$1.14K	﹤0.01%	1339
2015 Q3	–	Sell	-8	Closed	-$1K	–	973
2015 Q2	$1K	Buy	+8	New	+$1.15K	﹤0.01%	866

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

TCI Wealth Advisors's BIO Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2023, closing a stake of 16 shares — an estimated $7.67K sold.

TCI Wealth Advisors first reported a position in BIO in Q2 2015 and held it in 11 quarters. The position peaked at $14K in Q4 2021. 469 funds tracked by Wall St. Rank hold BIO as of Q2 2023.

TCI Wealth Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 16 Bio-Rad Laboratories Class A shares in Q2 2023, an estimated $7.67K.
TCI Wealth Advisors first reported a position in Bio-Rad Laboratories Class A in Q2 2015 and held it in 11 quarters.
TCI Wealth Advisors's Bio-Rad Laboratories Class A position peaked at $14K in Q4 2021.
469 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.